Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Amgen Inc

AMGN
Current price
268.93 USD +4.3 USD (+1.62%)
Last closed 262.75 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 140 932 792 320 USD
Yield for 12 month +10.46 %
1Y
3Y
5Y
10Y
15Y
AMGN
21.11.2021 - 28.11.2021

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Address: One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

288.28 USD

P/E ratio

21.0537

Dividend Yield

3.43 %

Current Year

+28 190 000 000 USD

Last Year

+26 323 000 000 USD

Current Quarter

+8 196 000 000 USD

Last Quarter

+6 903 000 000 USD

Current Year

+19 739 000 000 USD

Last Year

+19 917 000 000 USD

Current Quarter

+5 084 000 000 USD

Last Quarter

+5 097 000 000 USD

Key Figures AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 12 234 999 808 USD
Operating Margin TTM 8.15 %
PE Ratio 21.0537
Return On Assets TTM 6.29 %
PEG Ratio 2.3869
Return On Equity TTM 135.79 %
Wall Street Target Price 288.28 USD
Revenue TTM 28 189 999 104 USD
Book Value 11.64 USD
Revenue Per Share TTM 52.69 USD
Dividend Share 8.52 USD
Quarterly Revenue Growth YOY 19.8 %
Dividend Yield 3.43 %
Gross Profit TTM 19 917 000 000 USD
Earnings Share 12.48 USD
Diluted Eps TTM 12.48 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY -52.4 %
Profit Margin 23.83 %

Dividend Analytics AMGN

Champion - 10+ consecutive years of dividend increases

Dividend growth over 5 years

61 %

Continuous growth

12 years

Payout Ratio 5 years average

58 %

Dividend History AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 9
Ex Dividend Date 16.05.2024
Forward Annual Dividend Yield 3.43 %
Last Split Factor 2:1
Payout Ratio 46.97 %
Last Split Date 22.11.1999
Dividend Date 07.06.2024

Stock Valuation AMGN

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 21.0537
Forward PE 13.7741
Enterprise Value Revenue 6.986
Price Sales TTM 5.0812
Enterprise Value EBITDA 13.3056
Price Book MRQ 22.989

Financials AMGN

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AMGN

For 52 weeks

206.75 USD 327.16 USD
50 Day MA 277.8 USD
Shares Short Prior Month 11 113 890
200 Day MA 271.42 USD
Short Ratio 3.39
Shares Short 10 472 474
Short Percent 1.96 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics